By boosting innate immunity can eradicate aggressive prostate cancer in mice

Drug activates neutrophils instead of T cells, leading to cancer clearance

University of Chicago Medical Center

Cabozantinib, an FDA-approved drug for patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils -- the first-responders of the immune system -- to infiltrate the tumor. This novel approach, utilizing the innate immune system, produced near-complete clearance of invasive prostate cancers within 48 to 72 hours.

Journal Reference:

Akash Patnaik, Kenneth D. Swanson, Eva Csizmadia, Aniruddh Solanki, Natalie Landon-Brace, Marina P. Gehring, Katja Helenius, Brian M. Olson, Athalia R. Pyzer, Lily C. Wang, Olivier Elemento, Jesse Novak, Thomas B. Thornley, John M. Asara, Laleh Montaser, Joshua J. Timmons, Todd M. Morgan, Yugang Wang, Elena Levantini, John G. Clohessy, Kathleen Kelly, Pier Paolo Pandolfi, Jacalyn M. Rosenblatt, David E. Avigan, Huihui Ye, Jeffrey M. Karp, Sabina Signoretti, Steven P. Balk, Lewis C. Cantley. Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Anti-Tumor Innate Immunity. Cancer Discovery, 2017; CD-16-0778 DOI: 10.1158/2159-8290.CD-16-0778